What question did this study set out to answer?

To evaluate real-world standards of care in patients with relapsed/refractory multiple myeloma who are triple-class exposed.

March 24, 2022LeukemiaOpen Access

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Prospective study observes poor outcomes in relapsed/refractory multiple myeloma, highlighting the need for new treatments.

To evaluate real-world standards of care in patients with relapsed/refractory multiple myeloma who are triple-class exposed.
Multinational, prospective, non-interventional study
Inclusion of 248 patients with relapsed/refractory multiple myeloma
Median of 4.0 cycles of standard of care therapy administered
Overall response rate was 29.8% (95% CI: 24.2-36.0)
Median progression-free survival was 4.6 months (95% CI: 3.9-5.6)
Median overall survival was 12.4 months (95% CI: 10.3-NE)

Mateos et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark